CARsgen reports Phase-I CAR-GPC3 T Cell HCC trial results at ASCO 2017 annual meeting
CARsgen started CAR-CLD18.2 T cell clinical trial
CARsgen opened its new 33,000 sq.ft. cGMP Facility in Shanghai
CARsgen US entity opened in San Diego, CA
CARsgen Shanghai cell facility started construction
Series B of USD 30 M led by KTB.
CARsgen entered into Strategic Partnership with Shanghai Cancer Institute
CARsgen initiated world’s first Phase I CAR-GPC3 T Cell HCC trial
CARsgen started its leading CAR-T clinical trial on GBM
Series A of RMB 10 M by BVCF.
CARsgen Therapeutics founded in JUKE Biopark, Shanghai